Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABEDTIO
NCT07148960Phase 4Enrolling by invitation
- Sponsor
- West Virginia University
- Start
- Sep 2025
- Primary completion
- Jul 2027
- Modality
- Reversible Covalent Inhibitors, Cyclic Peptides, Antimicrobial Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of daptomycin, ceftaroline fosamil, cefazolin, ertapenem in Staphylococcus aureus bacteremia (SAB), sponsored by West Virginia University. Started Sep 2025; status: enrolling by invitation.
02
Drugs
daptomycinceftaroline fosamilcefazolinertapenem
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT07148960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07148960.